|
市場調查報告書
競爭分析：凝血因子
Competitor Analysis: Coagulation Factors
| 出版商 |
La Merie |
| 出版日期 |
2009年10月 |
商品編碼 |
102247 |
| 內容資訊 |
英文 126 Pages |
| 價格 |
|
|
競爭分析：凝血因子 是由出版商La Merie在2009年10月所出版的。
這份英文市場調查報告書包含126 Pages 價格從美金705起跳。
本報告書內容包括：遺傳性/後天性的凝血障礙治療的局部性/全身供給血漿的由來/替換凝血因子製藥的領域來提供競爭評價。內容綱要摘記如下：
目次
- 凝固因子VIII
- 凝固因子IX
- 凝固因子VII
- Von Willebrand氏因子(vWF)
- 纖維素原
- 凝固因子V及XI
- 凝固因子X
- 凝固因子XIII
- 纖維蛋白原及凝血酵素局部止血藥
- 凝血酵素局部止血藥
- 凝血複合體濃縮製藥
- 凝固因子製藥廠及研究開發生產線
- 關於La Merie
血液凝固因子製藥廠商及研究開發生產線
- Abraxis Biosciences
- Amsterdam Molecular Therapeutics
- Angiotech
- Apitope
- Asklepios Biopharmaceutical
- Baxter
- Bayer Schering Pharma
- Bio Products Laboratory (BPL)
- Biogen Idec
- Biotest
- Biovitrum
- Catalyst Biosciences
- China Biologic Products
- Crucell
- CSL
- Ethicon (J&J)
- Genzyme
- Green Cross
- Grifols
- GTC Biotherapeutics
- Haemacure
- Inspiration Biopharmaceuticals
- Intas Biopharmaceuticals
- Ipsen
- Jerini
- 化學及血清療法研究所
- Kamada
- Kedrion
- King Pharmaceuticals
- LFB
- Lipoxen
- Maxygen
- MDRNA
- MediVas
- 持田製藥
- National Bioproducts Institute (NBI)
- Nautilus Biotech (HanAll Pharmaceuticals)
- Nektar Therapeutics
- Neose Technologies
- Novo Nordisk
- Nycomed
- Octapharma
- Oxford Biomedica
- Pharming
- ProFibrix
- ProGenetics
- PROLOR Biotech
- Recoly
- Roche
- Sanquin
- Shanghai RAAS
- Sinobiomed
- SK Chemicals
- Talecris Biotherapeutics
- Thrombotargets
- VIRxSYS
- Wyeth
- Zymogenetics
Abstract
Report Statistics
- Pages: 126
- Release Date: October of 2009
- Format: PDF
Product description
The present Competitive Intelligence Report about Coagulation Factors provides
a competitor evaluation in the field of plasma-derived and recombinant
coagulation factors for topical or systemic administration to treat hereditary
or acquired coagulation disorders as of October 2009. Purchase of the
downloadable pdf report includes a 6-month online access to the data of the
report and any updates since the publication date. Credentials to access the
database will be sent by e-mail and allow online work with the project data to
print or export an individual report.
The market size of recombinant and plasma-derived coagulation factor products
exceeded US$ 7.5 bln in 2008, the majority (US$ 5.5 bln) generated by
recombinant proteins. Replacement of plasma-derived coagulation factors by
marketed recombinant molecules is ongoing and will further increase by new
recombinant coagulation factors in development. In light of ongoing expiration
of substance patents, about 40 new recombinant coagulation factor projects are
in the pipeline indicating a changing marketplace over the next decade. New
players are competing and will challenge established manufacturers and
marketers of coagulation factor products.
Apart from recombinant products, plasma-derived coagulation factors still play
a considerable role, albeit bovine derived products are considerably being
challenged by human recombinant and plasma-derivd products. Coagulation
factors not only are being used for systemic treatment of hereditary
coagulation factor deficiencies, but also for topical or systemic treatment of
bleedings.
The report includes a compilation of current active projects in research and
development of topical and systemic coagulation factors obtained by
purification of human plasma or by recombinant DNA technology. In addition,
the report lists company-specific R&D pipelines of coagulation factors.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Table of Contents
Index
- Coagulation Factor VIII
- Coagulation Factor IX
- Coagulation Factor VII
- Von Willebrand Factor (vWF)
- Fibrinogen
- Coagulation Factors V and XI
- Coagulation Factor X
- Coagulation Factor XIII
- Topical Fibrinogen and Thrombin Products
- Topical Thrombin Products
- Prothrombin Complex Concentrates
Corporate Coagulation Factor Product and R&D Pipelines
- About La Merie
- Corporate Coagulation Factor Product and R&D Pipelines
- Abraxis Biosciences
- Amsterdam Molecular Therapeutics
- Angiotech
- Apitope
- Asklepios Biopharmaceutical
- Baxter
- Bayer Schering Pharma
- Bio Products Laboratory (BPL)
- Biogen Idec
- Biotest
- Biovitrum
- Catalyst Biosciences
- China Biologic Products
- Crucell
- CSL
- Ethicon (J&J)
- Genzyme
- Green Cross
- Grifols
- GTC Biotherapeutics
- Haemacure
- Inspiration Biopharmaceuticals
- Intas Biopharmaceuticals
- Ipsen
- Jerini
- Kaketsuken
- Kamada
- Kedrion
- King Pharmaceuticals
- LFB
- Lipoxen
- Maxygen
- MDRNA
- MediVas
- Mochida Pharmaceutical
- National Bioproducts Institute (NBI)
- Nautilus Biotech (HanAll Pharmaceuticals)
- Nektar Therapeutics
- Neose Technologies
- Novo Nordisk
- Nycomed
- Octapharma
- Oxford Biomedica
- Pharming
- ProFibrix
- ProGenetics
- PROLOR Biotech
- Recoly
- Roche
- Sanquin
- Shanghai RAAS
- Sinobiomed
- SK Chemicals
- Talecris Biotherapeutics
- Thrombotargets
- VIRxSYS
- Wyeth
- Zymogenetics
|
